3rd time the charm?

For the third time since early 2007, cardiovascular and metabolic company Aegerion Pharmaceuticals Inc. has filed for an IPO of up to $86.3 million. Over that period, the company has moved lead candidate lomitapide from Phase II testing into Phase III.

Lomitapide is in an open-label Phase III trial to treat homozygous familial hypercholesterolemia (hoFH), which is expected to complete in 2H11. NDA and MAA submissions are expected before the end of 2011 and in 2012, respectively...